Compare BLRX & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLRX | PRSO |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 13.4M |
| IPO Year | 2010 | 2000 |
| Metric | BLRX | PRSO |
|---|---|---|
| Price | $3.06 | $0.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.00 | $3.00 |
| AVG Volume (30 Days) | 14.6K | ★ 415.5K |
| Earning Date | 05-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,573,000.00 |
| Revenue This Year | N/A | $18.48 |
| Revenue Next Year | N/A | $53.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.99 |
| 52 Week Low | $2.15 | $0.73 |
| 52 Week High | $4.75 | $2.37 |
| Indicator | BLRX | PRSO |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 39.20 |
| Support Level | $3.05 | N/A |
| Resistance Level | $3.11 | $0.94 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 48.30 | 14.70 |
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.